© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
January 25, 2022
Key opinion leaders conclude their discussion on plaque psoriasis by commenting on the potential for research into the genetic origin of disease, possible biomarkers, and treatment options with greater efficacy.
A group of specialists discusses unmet needs in psoriatic disease including physician education about biologics and research about treatment options for pediatric patients, patients with malignancies, and patients who are pregnant.
January 18, 2022
A panel of experts builds a lively discussion on the evolving treatment landscape in plaque psoriasis and highlights the emergence of IL-23 inhibitors as a new class of biologic agents.
Thought leaders in the management of plaque psoriasis share personal insights into factors to consider when treating patients with IL-23 inhibitors, including when to switch biologic agents.
Daridorexant Provides Positive Phase 3 Results in Adults with Insomnia
Pandemic-Trauma Stress Symptoms: Nightmares Significantly Increased Among Adults
AI Algorithm May Help Identify Eligibility for Diabetic Retinopathy Clinical Trials